WT1 and acute myeloid leukemia: To overcome this, we utilized peripheral blood mononuclear cells (PBMCs) from healthy donors (n = 6) and acute myeloid leukemia (AML) patient bone marrow mononuclear cells (BMMCs) (n = 6) to enhance WT1-specific T-cell responses through peptide-pulsing (study flow shown in Fig. 1A).